While medicines consisting of modified RNA have been decades in the making, it took the pressure of a global pandemic to push the promising technology past hurdles and onto the market. Thanks to a great deal of innovation, mRNA is now a household name and a rapidly expanding industry for the biopharma world beyond COVID-19. Over 250 potential mRNA therapies are currently being investigated in cancer, with more than 500 in other indications.
Tag Archive for: mRNA vaccines
The Bill & Melinda Gates Foundation will give $40 million, including to a Belgian biotech company and two leading African vaccine manufacturers, in a bid to boost access to mRNA vaccines for protection against various diseases in Africa.
As the COVID pandemic continues, Moderna wants to show that its mRNA technology can treat more than just COVID, and has launched a video spot, “Welcome to the mRNAge,” that will appear online, on TV, and elsewhere.
Pfizer and BioNTech sued Moderna in London in September, seeking to revoke two of Moderna’s patents in relation to its messenger RNA (mRNA) vaccines.
The European Union has offered free COVID-19 vaccines to China, the EU executive said on Tuesday, as infections there surged following Beijing’s relaxation of its “zero-COVID” policies.
Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales, seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday.
Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.
The United States has administered more than 7,300 doses of Novavax Inc.’s (NVAX.O) COVID-19 shot, which health officials hope will convince more people to opt for vaccinations as it is based on a technology that has been in use for decades.
CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.
Moderna announced that the company’s Omicron-containing COVID-19 booster candidate, mRNA-1273.214, demonstrated superior antibody response against Omicron in its Phase II/III study. The booster contains the original COVID-19 vaccine, Spikevax, as well as a vaccine targeting the Omicron variant.